# A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Source: https://onco.cc/trials/nct07578337/  
OnCo record `nct07578337` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, nab-paclitaxel and botensilimab in pancreatic cancer, run by Nelum Corp, not yet recruiting.

## Summary

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease. is a phase 2, randomised interventional study registered as NCT07578337 by Nelum Corp, with a registry enrolment figure of 40 participants, started 2026-07-15 and due to reach its primary completion in 2029-02-28. Interventions recorded: Gemcitabine (1000 mg/m2); Nab-paclitaxel (Abraxane); NLM-001; Botensilimab; Balstililmab. Conditions listed: Untreated; Advanced Pancreatic Cancer. Primary outcome: To evaluate the response rate in each of the study arms, assessed according to iRECIST criteria, including the confirmation of progression to distinguish true progression from potential pseudoprogression.. Pancreatic eligibility wording from the registry: "Histological or cytological diagnosis of pancreatic adenocarcinoma". Sites: Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: NUMANTIA-2
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07578337
- Phase: 2
- Setting: A Randomized Phase II Study of Priming Treatment With the Hedgehog Inhibitor NLM-001 Prior to Gemcitabine/Nab-Paclitaxel (GNab-P) plusBotensilimab and Balstilimab (Bot/Bal) Versus GNab-P in Patients With Previously Untreated Advanced Pancreatic Cancer (NUMANTIA-2)
- Sponsor: Nelum Corp
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07578337: https://clinicaltrials.gov/study/NCT07578337

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Botensilimab](https://onco.cc/drugs/botensilimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07578337.json